Status:
TERMINATED
Open-Label Treatment With MPC-7869 for Patients With Alzheimer's Who Previously Participated in an MPC-7869 Protocol
Lead Sponsor:
Myrexis Inc.
Conditions:
Alzheimer's Disease
Eligibility:
All Genders
55+ years
Phase:
PHASE3
Brief Summary
Open-label treatment with MPC-7869 for participants in a previous randomized study.
Eligibility Criteria
Inclusion
- Participation in a previous MPC-7869 randomized protocol
- Have had a diagnosis of probable Alzheimer's disease.
- Men or women ages 55 years or greater and living in the community at the time of enrollment (i.e., not living in a rest home or nursing care facility).
- Signed the subject Informed Consent Form and is willing and able to participate for the duration of the study.
- Female subjects must be surgically sterile or postmenopausal for \> 1 year.
- Subjects must have a reliable caregiver who can read, understand and speak English or Spanish.
Exclusion
- History or evidence of, active malignancy, except for basal cell carcinoma or squamous cell carcinoma of the skin, within the 24 months prior to entry. Men with prostate cancer may be enrolled at the discretion of the sponsor.
- Chronic or acute renal, hepatic or metabolic disorder.
- Use of any investigational therapy within 30 days, or 5 half-lives, whichever is longer, and/or use of AD immunotherapy prior to screening.
Key Trial Info
Start Date :
September 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2008
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT00380276
Start Date
September 1 2006
End Date
December 1 2008
Last Update
August 5 2008
Active Locations (90)
Enter a location and click search to find clinical trials sorted by distance.
1
Alabaster, Alabama, United States
2
Huntsville, Alabama, United States
3
Phoenix, Arizona, United States
4
Sun City, Arizona, United States